You are here: Industry Insights > Kadimastem

News List

AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial europeanpharmaceuticalreview
December 17, 2020
Amyotrophic lateral sclerosis (ALS) patients treated with AstroRx® had a 45 percent reduction in their disease progression rate.
Kadimastem Reports Positive Interim Results of ALS AstroRx Trial americanpharmaceuticalreview
August 10, 2020
Kadimastem announced its lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company's Phase 1/2a clinical trial in ALS.
Kadimastem Announces Results of Cohort A of ALS Trial americanpharmaceuticalreview
September 26, 2019
Kadimastem announced promising interim results of cohort A of its Phase 1/2a clinical trial for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).
Kadimastem completes cell transplantation of AstroRx in ALS patients biospectrumasia
March 04, 2019
The objective of the trial is to evaluate the safety and efficacy of AstroRx® in patients
Kadimastem Announces the Completion of Cell Transplantation of AstroRx in ALS Patients americanpharmaceuticalreview
February 28, 2019
Kadimastem announced the completion of cell transplantation (AstroRx®) in 5 patients who were enrolled in Cohort A for its clinical trial in ALS....
AFDR, Kadimastem to receive bi-national grant to explore diabetes solution biospectrumasia
October 17, 2018
AFDR is a non-profit organization dedicated to promoting treatment for diabetes in Australia. Its researchers have developed a unique encapsulation device that enables the implantation of insulin-producing cells and provides protection against the immune
Kadimastem Receives Approval for ALS Patient Clinical Trial americanpharmaceuticalreview
June 22, 2017
Kadimastem announced it had received approval from the IRB of the Hadassah Ein Kerem Hospital for the phase 1/2a clinical trial in ALS patients using the cell therapy product developed by the company.